CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Clinical trials for CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY explained in plain language.
Never miss a new study
Get alerted when new CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY trials appear
Sign up with your email to follow new studies for CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug mimics IVIg to tame nerve inflammation
Disease control OngoingThis study tests a new drug called NVG-2089 in 60 adults with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve condition that causes weakness and numbness. The drug is designed to work like IVIg, a standard treatment, by calming the immune system and reducing inf…
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Phase: PHASE2 • Sponsor: Nuvig Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 11:18 UTC
-
Could a stem cell transplant halt autoimmune attacks on the brain?
Disease control OngoingThis study tests a strong chemotherapy combination followed by a stem cell transplant in people with autoimmune neurologic diseases like multiple sclerosis or stiff person syndrome that haven't responded to standard treatments. The goal is to weaken the overactive immune system s…
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 26, 2026 11:10 UTC
-
CIDP cure hopes dashed: key study withdrawn before enrolling a single patient
Disease control TerminatedThis study aimed to see if the drug Rituximab could help people with a nerve disease called CIDP stop their current medications and achieve long-term remission. Researchers planned to treat 48 patients in three groups based on specific antibodies. However, the study was withdrawn…
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Phase: PHASE2 • Sponsor: University of Kansas Medical Center • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
New drug batoclimab tested for Long-Term safety in nerve disorder patients
Disease control ENROLLING_BY_INVITATIONThis study looks at the long-term safety of a drug called batoclimab for adults with chronic inflammatory demyelinating polyneuropathy (CIDP), a condition that causes weakness and numbness. About 108 people who completed a previous study will get weekly injections for up to a yea…
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Phase: PHASE2 • Sponsor: Immunovant Sciences GmbH • Aim: Disease control
Last updated May 19, 2026 12:01 UTC
-
Own stem cells tried for rare nerve disease
Disease control NO_LONGER_AVAILABLEThis study tests the safety and early effects of using a patient's own stored stem cells to treat chronic inflammatory demyelinating polyneuropathy (CIDP), a rare nerve disorder. Only one patient who has banked their stem cells at the sponsor's facility can join. The treatment in…
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Sponsor: Hope Biosciences Research Foundation • Aim: Disease control
Last updated May 18, 2026 12:13 UTC
-
New test aims to predict falls in muscle disease patients
Knowledge-focused ENROLLING_BY_INVITATIONThis study aims to create a simple test to determine the risk of falling for people with neuromuscular disorders like muscular dystrophy, ALS, and myasthenia gravis. Researchers will evaluate how well a series of physical tasks (like standing up, walking, and balancing) can predi…
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Sponsor: LMU Klinikum • Aim: Knowledge-focused
Last updated May 26, 2026 11:12 UTC